Drugs Made In America Acquisition IIDMII 15 3-1 Month Momentum % is 1.00% as of Jul. 11, 2026. GuruFocus rates DMII with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 530 Diversified Financial Services companies, Drugs Made In America Acquisition II ranks better than 65.85% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-11), Drugs Made In America Acquisition II's 3-1 Month Momentum % is 1.00%.
DMII's 3-1 Month Momentum % is ranked better than 65.85% of 530
companies
in the Diversified Financial Services industry
Industry Median: 0.71
vs DMII: 1.00
Drugs Made In America Acquisition II (NAS:DMII) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Drugs Made In America Acquisition II 3-1 Month Momentum % Related Terms
DMII vs BCSS, EVAC, CEPF: 3-1 Month Momentum % Comparison
For the Shell Companies subindustry, Drugs Made In America Acquisition II's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Drugs Made In America Acquisition II 3-1 Month Momentum % vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Drugs Made In America Acquisition II's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Drugs Made In America Acquisition II's 3-1 Month Momentum % falls into.
Drugs Made In America Acquisition II (NAS:DMII) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Drugs Made In America Acquisition II (DMII) has a 3-1 Month Momentum % of 1.00% as of Jul. 11, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Drugs Made In America Acquisition II and its competitors. According to the industry distribution chart, Drugs Made In America Acquisition II ranks #181 out of 530 companies in the Diversified Financial Services industry, placing it in the top 34.2%.
Is Drugs Made In America Acquisition II's 3-1 Month Momentum % too high?
Drugs Made In America Acquisition II's current 3-1 Month Momentum % is 1.00%. The Diversified Financial Services industry median 3-1 Month Momentum % is 0.71. Drugs Made In America Acquisition II's value of 1.00% is 40.8% above this industry median. Based on the distribution chart, Drugs Made In America Acquisition II ranks #181 out of 530 companies in the Diversified Financial Services industry, which is above the industry midpoint. Overall, Drugs Made In America Acquisition II has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Drugs Made In America Acquisition II's 3-1 Month Momentum % compare to BCSS and EVAC?
According to the Diversified Financial Services industry distribution chart, Drugs Made In America Acquisition II ranks #181 out of 530 companies for 3-1 Month Momentum %. This puts Drugs Made In America Acquisition II in the upper half of its industry. The industry median 3-1 Month Momentum % is 0.71. Drugs Made In America Acquisition II's value of 1.00% is 40.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Diversified Financial Services company?
The median 3-1 Month Momentum % among Diversified Financial Services companies is 0.71, based on 530 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Drugs Made In America Acquisition II's current 3-1 Month Momentum % of 1.00% is 40.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Drugs Made In America Acquisition II and its competitors. For the Diversified Financial Services industry, the median 3-1 Month Momentum % is 0.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Drugs Made In America Acquisition II's current 3-1 Month Momentum % is 1.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drugs Made In America Acquisition II stock overvalued right now?
Drugs Made In America Acquisition II (DMII) has a current 3-1 Month Momentum % of 1.00%. The current 3-1 Month Momentum % is 1.00% and 40.8% above the Diversified Financial Services industry median of 0.71. Drugs Made In America Acquisition II's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Drugs Made In America Acquisition II (DMII), the current 3-1 Month Momentum % is 1.00% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Drugs Made In America Acquisition II Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMII has been successfully added to your 